Cancer Therapy : Preclinical Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p 53 wild-type and p 53 mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway